Brevan Howard Capital Management
IPSC icon

Brevan Howard Capital Management’s Century Therapeutics IPSC Stock Holding History

Brevan Howard Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-96,641
Closed -$218K – 2313
2026
Q1 		$218K Buy
+96,641
New +$203K ﹤0.01% 1844

Other funds holding IPSC

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Brevan Howard Capital Management's IPSC Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Century Therapeutics (IPSC) in Q2 2026, closing a stake of 96,641 shares — an estimated $218K sold.

Brevan Howard Capital Management first reported a position in IPSC in Q1 2026 and held it in 1 quarter. The position peaked at $218K in Q1 2026. 100 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Century Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 96,641 Century Therapeutics shares in Q2 2026, an estimated $218K.
  • Brevan Howard Capital Management first reported a position in Century Therapeutics in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Century Therapeutics position peaked at $218K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.